microdoses of semaglutide Semaglutide Microdose

New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our

27.23

★★★★☆4.6 (108)

GLP-1 RA prescription trends: January 2018 – September 2025

24.41

★★★★★4.9 (191)

Buyer beware. New data points to a higher likelihood of adverse events from using compounded GLP-1 meds versus the fda approved branded versions. No I dong get paid by these companies. In fact the

25.32

★★★★★4.5 (46)

The Rising Tide of GLP-1 Costs: Can Your Health Plan Stay Afloat?

25.31

★★★★★4.7 (27)

FDA issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of

24.49

★★★★★4.5 (171)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

21.79

★★★★★4.8 (183)

Growth, Volume, Price: The Skinny on GLP-1 Medications -

26.37

★★★★★4.7 (87)